An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib.
Dean, Emma J
AffiliationDrug Development Unit, The Royal Marsden/The Institute of Cancer Research, Downs Road, Sutton, SM2 5PT, UK
MetadataShow full item record
AbstractOlaparib is poorly soluble, requiring advanced drug delivery technologies for adequate bioavailability. Sixteen capsules/day are required for the approved 400 mg twice-daily dose; a tablet formulation was developed to reduce pill burden. This clinical trial evaluated the optimal dose and administration schedule of the tablet formulation.
CitationAn adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib. 2016, 11 (3):401-15 Target Oncol